SAN FRANCISCO -- Perioperative sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) achieved a "promising" clinical ...
Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 vs BEPx3.
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...
In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results